Tennessee Oncology, PLLC - Smyrna

Clinical research site in Smyrna, Tennessee · 300 STONECREST BLVD, STE 400, SMYRNA, TN 37167-5688 · (615) 355-1770

As of August 2026, 4 paid clinical trials are recruiting at Tennessee Oncology, PLLC - Smyrna in Smyrna, Tennessee. Active studies at this site cover conditions such as Advanced/Metastatic Urothelial Cancer, Cancer of the Prostate and Hormone Sensitive Prostate Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: August 31, 2026.

New trial at Tennessee Oncology, PLLC - Smyrna? We'll email you when one opens.

Recruiting clinical trials at Tennessee Oncology, PLLC - Smyrna (4)

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

for Urothelial Cancer

133 locations incl. Fayetteville

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07421700·Phase 1, Phase 2·Recruiting·Listed Feb 2026

Apply to this trial

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

for Carcinoma, Renal Cell

109 locations incl. Phoenix

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07227415·Phase 1, Phase 2·Recruiting·Listed Nov 2025

Apply to this trial

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

for Non-small Cell Carcinoma

218 locations incl. Alabaster

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07144280·Phase 3·Recruiting·Listed Aug 2025

Apply to this trial

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

for Metastatic Castration Sensitive Prostate Cancer (mCSPC)

124 locations incl. Huntsville

Sponsor: Pfizer

Sex: Male·Age: 18+

Code: NCT07028853·Phase 3·Recruiting·Listed Jun 2025

Apply to this trial

Get new-trial alerts for Tennessee Oncology, PLLC - Smyrna

We'll email you whenever a new clinical trial starts recruiting at this research site in Smyrna, TN. Unsubscribe anytime.

Is this your research site?

This page is built from public ClinicalTrials.gov records. If you work here, we can correct it, send you the patients who apply, and build you a free website from your real studies — verify it with your work email, or read what we do for research sites.

Explore more

Paid clinical trials in Smyrna, TN · Tennessee clinical trials

Tennessee Oncology, PLLC - Smyrna

Recruiting clinical trials at Tennessee Oncology, PLLC - Smyrna (4)

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

Get new-trial alerts for Tennessee Oncology, PLLC - Smyrna

More research sites in Smyrna

Is this your research site?

Explore more